Clinical Trials Logo

Cancer, Metastatic clinical trials

View clinical trials related to Cancer, Metastatic.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05739838 Active, not recruiting - Clinical trials for Periodontal Diseases

Low-Level Laser Effects on Orthodontic Tooth Movement of Periodontally Compromised Patients.

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

To investigate the effect of Low Level Laser therapy on orthodontic tooth movement of periodontally compromised patients by evaluating the rate of orthodontic tooth movement and the level of Osteocalcin in the gingival crevicular fluid.

NCT ID: NCT04870177 Active, not recruiting - Ovarian Neoplasms Clinical Trials

Study of AK112 in the Treatment of Advanced Gynecological Tumors

Start date: March 16, 2021
Phase: Phase 2
Study type: Interventional

A phase II study to evaluate the efficacy and safety of AK112 in subjects with advanced gynecological tumors.

NCT ID: NCT03936075 Active, not recruiting - Cancer, Breast Clinical Trials

Guided Imagery & Music in Cancer

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

This is an RCT pilot study to explore the potential effects of the Guided Imagery & Music method for women with breast or gynecologic cancer, during active treatment. The study explores the potential impact in quality of life parameters such as mood, fatigue, and hope.

NCT ID: NCT03491631 Active, not recruiting - Tumor, Solid Clinical Trials

Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors

Start date: November 20, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial is designed to efficiently identify the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) for the combination therapy regimen of the IDO1 inhibitor SHR9146 when administered in combination with immune checkpoint PD-1 inhibitor SHR-1210 plus VEGFR inhibitor Apatinib or not in subjects with advanced/metastatic solid tumors. All subjects will receive the same standard SHR-1210 plus Apatinib (only three drugs group)regimen, while SHR9146 in doses increasing from 100 mg twice daily to, potentially, 600 mg twice daily. Once the recommended regimen has been identified, subjects with the selected tumor type will be enrolled into expansion cohorts based upon prior safety and tolerability data.

NCT ID: NCT03347162 Active, not recruiting - Cancer Clinical Trials

Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer

Start date: December 1, 2017
Phase:
Study type: Observational

PURPOSE: To determine the prognostic properties of a comprehensive evaluation of body composition and physical function in patients with GI-HEP cancer from point of diagnosis and throughout the treatment trajectory. GI-HEP: Patients with tumors of the upper gastrointestinal or hepatobiliary tract, specifically tumors of the esophagus, gastro-esophageal junction, stomach, primary tumors of the liver or biliary tract, as well as colorectal liver metastasis or tumors of the pancreas.